Vaxartto Present at World Vaccine Congress Washington 2025 on April 23
Vaxart (Nasdaq: VXRT) has announced its participation in the World Vaccine Congress Washington 2025, scheduled for April 23, 2025, in Washington, D.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vaxart (Nasdaq: VXRT) has announced its participation in the World Vaccine Congress Washington 2025, scheduled for April 23, 2025, in Washington, D.C. Two key executives will deliver presentations at the event:
Dr. James F. Cummings, Chief Medical Officer, will present on 'Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination' at 1:10 p.m. ET in Room 207A.
Dr. Sean Tucker, Founder and Chief Scientific Officer, will discuss 'Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection' at 3:10 p.m. ET in the same room. The company has been a regular presenter at this annual Washington, D.C. event.
Details
News Market Reaction – VXRT
The recorded move for VXRT in the trading session of this news was -1.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Washington 2025 in Washington, D.C. on Wednesday, April 23, 2025. The Company has appeared repeatedly at the annual event in Washington, D.C.
Presentation Information:
Title: Moving the needle: Blocking transmission and boosting existing vaccines by oral tablet vaccination
Speaker: Dr. James F. Cummings
Date: Wednesday, April 23, 2025
Time: 1:10 p.m. ET
Room: 207A
Title: Immune profiling on an oral norovirus vaccine candidate; correlates of protection for disease and infection
Speaker: Dr. Sean Tucker
Date: Wednesday, April 23, 2024
Time: 3:10 p.m. ET
Room: 207A
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
This press release was published by a CLEAR® Verified individual.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.